Biotech Stock Mailbag: NeoStem, MannKind, Inovio

Posted: Published on January 12th, 2014

This post was added by Dr. Richardson

Welcome to this week's Biotech Stock Mailbag. Before I kick off, a few housekeeping items to note:

I launched a new blog on TheStreet this week. It's called Adam's Biotech Beat. I know, not the most original name but straightforward. I'll have more to say about the blog later, but please bookmark the page and check it often. You'll see me posting a lot of intraday news and analysis, plus it's a great way to keep track of all my tweets.

The J.P. Morgan Healthcare Conference starts Monday in San Francisco. I'm flying out there Sunday and will be providing live coverage from the presentations and breakout rooms.

Chelsea Therapeutics (CHTP) and its hypotension drug Northera will be the star of an FDA advisory panel on Tuesday. I have invited healthcare investor and TheStreet contributing writer Aafia Chaudhry to live-blog the Chelsea panel, so please tune into that.

More:
Biotech Stock Mailbag: NeoStem, MannKind, Inovio

Related Posts
This entry was posted in FDA Stem Cell Trials. Bookmark the permalink.

Comments are closed.